BidaskClub upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a buy rating in a report released on Tuesday morning, BidAskClub reports.

Several other equities research analysts have also commented on the stock. ValuEngine lowered shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, August 1st. Guggenheim initiated coverage on shares of ANI Pharmaceuticals in a research note on Thursday, September 12th. They set a buy rating and a $76.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. ANI Pharmaceuticals presently has an average rating of Buy and an average price target of $86.40.

Shares of ANIP opened at $72.42 on Tuesday. ANI Pharmaceuticals has a twelve month low of $36.92 and a twelve month high of $86.96. The firm’s fifty day simple moving average is $70.47 and its 200-day simple moving average is $71.95. The firm has a market capitalization of $879.55 million, a price-to-earnings ratio of 15.71 and a beta of 2.22. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.18 by $0.26. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business had revenue of $54.36 million for the quarter, compared to analyst estimates of $55.20 million. During the same period last year, the business earned $1.13 EPS. The company’s revenue was up 15.0% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals will post 5.29 earnings per share for the current fiscal year.

In related news, major shareholder Meridian Venture Partners Ii L sold 19,860 shares of ANI Pharmaceuticals stock in a transaction on Friday, August 9th. The shares were sold at an average price of $71.70, for a total transaction of $1,423,962.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 98,451 shares of company stock worth $7,006,801 over the last quarter. 24.70% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth $32,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ANI Pharmaceuticals by 237.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock worth $65,000 after purchasing an additional 559 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in ANI Pharmaceuticals by 55,466.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 1,664 shares during the last quarter. BerganKDV Wealth Management LLC purchased a new position in ANI Pharmaceuticals during the 1st quarter worth $141,000. Finally, Convergence Investment Partners LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth $164,000. Hedge funds and other institutional investors own 70.77% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: Catch-Up Contributions

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.